Rheumatoid Arthritis Clinical Trial
— RACATOfficial title:
CSP #551 - Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy
Rheumatoid arthritis (RA) is a chronic inflammatory disease of the joints leading to joint
destruction, with significant long-term morbidity and mortality. Early treatment of RA
patients with disease-modifying antirheumatic drugs (DMARDs) significantly decreases these
complications. Methotrexate (MTX) is an excellent, economical first-line DMARD used to treat
a majority of RA patients. While most patients respond well to MTX, many continue to have
active disease. Therefore, understanding how to best treat RA patients with active disease
despite MTX therapy is critically important. Although a number of therapies with
significantly different economic implications have been shown to be effective when added to
MTX, no trial has directly compared active therapies. This study will compare therapeutic
strategies using two regimens with proven efficacy when added to MTX therapy; a)
hydroxychloroquine and sulfasalazine (cost ~ $1000 per year); b) the tumor necrosis factor
inhibitor, etanercept (cost ~ $12,000 per year).
We propose a bi-national multi-center randomized, double-blind equivalency trial comparing
(A) the strategy of initially adding hydroxychloroquine and sulfasalazine to MTX in patients
with active disease despite MTX, with a switch at 24 weeks to etanercept in nonresponders to
(B) a strategy of adding etanercept to MTX, with a switch to hydroxychloroquine and
sulfasalazine in nonresponders at 24 weeks. If we find that the strategy of first adding
hydroxychloroquine and sulfasalazine to MTX identifies a subset of responsive patients and
that there is no harm to nonresponders because of early rescue with etanercept, then this
less expensive option should become the standard treatment for MTX resistant patients.
Four hundred and fifty RA patients with active disease despite treatment with MTX as
indicated by a Disease Activity Score with 28 joints (DAS28) of >4.4 units will be
randomized. A DAS improvement of <1.2 (validated as clinically significant) at 24 weeks will
be used to identify early nonresponder who will switch therapy. Subjects with a DAS28
improvement of > 1.2 at 24 weeks will remain on their initial therapy. The primary endpoint
is the change of DAS 28 scores from baseline to 48 weeks. The secondary endpoint is
comparison of radiographic progression of disease at 48 weeks, as measured by the change in
Sharp score. Economic and functional outcomes will be assessed and a serum and DNA bank will
be established to evaluate potential biomarkers predictive of treatment response/toxicity
and disease progression. This trial will recruit 450 subjects over 40 months. At the end of
the 48 week blinded active therapy portion of the trial, the blind will be broken and data
will be collected in an open fashion until all 450 patients have completed the 48 week
portion of the trial.
Status | Completed |
Enrollment | 353 |
Est. completion date | May 2012 |
Est. primary completion date | December 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - All patients must fulfill ACR classification criteria for rheumatoid arthritis. - All patients must have been 16 years of age or older at time of diagnosis of rheumatoid arthritis. - All patients must be 18 years of age or older at the time of entry into the study. - All patients will have been receiving oral or subcutaneous methotrexate 15 to 25 mg/week (unless intolerant and on a minimum 10 mg/week) at a constant dose for at least 4 weeks, and on any methotrexate for no less than 12 weeks. - All patients will have active disease as defined by a DAS28 of greater than or equal to 4.4. - If patients are receiving corticosteroids, they must have been on stable dose (less than or equal to 10 mg prednisone or equivalent) for at least two weeks prior to screening. - If patients are using non-steroidal anti-inflammatory drugs (NSAIDs), they must be on stable doses for at least one week prior to screening. - If patients have taken leflunomide, cyclosporine, gold, Anakinra, azathioprine, or penicillamine in combination with methotrexate, they must have stopped this therapy at least 8 weeks prior to randomization. - Laboratory tests must meet the following criteria within 2 weeks of randomization: - Serum creatinine 1.8 mg/dL - Hemoglobin 9 g/dL - WBC 3000 mc/L - Neutrophils 1000 mc/L - Platelets 100,000 mc/L - Serum transaminase level (AST or ALT, whichever is followed at the site) not exceeding 1.2 times upper limit of normal. - Albumin no less than 1.0 g/dL (10 g/L) below lower limit of normal. Anything below lower limit of normal must have been stable (or improving) for no less than 90 days. Stable is defined as changes of no more than 0.2 g/dL (2 g/L). - All patients must be capable of giving informed consent and able to adhere to study visit schedule. - Subject or designee must have the ability to self-inject investigational product or have a caregiver who can inject subcutaneous injections - Subjects must meet one of the following criteria with regard to tuberculosis. PPD must be within 180 days of randomization if the patient has no recent exposure/travel history, or within 90 days if the patient has a recent exposure/travel history. - Negative PPD; or - Positive PPD <5 mm, with a negative chest x-ray; or - Positive PPD >5mm, treated for at least 28 days with INH. - Subjects with an Erythrocyte sedimentation rate (ESR) of less than or equal to 10 and a tender and swollen joint count of at least 10 and does not qualify for the study using the DAS28, will be allowed to use the DAS28-CRP rather than the traditional DAS28 to determine eligibility. Exclusion Criteria: - Previous intolerance to methotrexate (unless able to tolerate at least 10 mg/week) - Sensitivity to study medications - Previous treatment with methotrexate, sulfasalazine or hydroxychloroquine in combination with each other for longer than 4 weeks duration. No combination use is allowed within 4 weeks of screening. - No bed or wheelchair-bound patients - Previous treatment with a TNF- inhibitor (etanercept, infliximab or adalimumab) for more than 5 weeks of therapy. Previous treatment with TNF- inhibitor must have been stopped for reasons other than toxicity or efficacy. No TNF- inhibitor therapy is allowed within the following time frames: - Last dose of etanercept must have been at least 4 weeks before screening. - Last dose of adalimumab or infliximab must have been at least 8 weeks prior to screening. Example of an eligible patient: A patient found he could not afford the co-pays for a TNF inhibitor after two doses and stopped taking the medication two months before being evaluated for this trial. - Evidence of important acute or chronic infections (no IV antibiotics within 1 month, and no PO antibiotics within 2 weeks) - Pregnant or nursing women - Women of childbearing potential or their partners who are not practicing an acceptable form of birth control as defined by investigator - Active substance abuse or psychiatric illness likely to interfere with protocol completion - History of multiple sclerosis, transverse myelitis, or optic neuritis - History of macular degeneration unless patient has letter from their ophthalmologist that will allow for participation in trial - New York Heart Association Class III or IV congestive heart failure - Active malignancy (other than in situ cervical cancer or non-melanoma skin cancer), or history of lymphoma - History of HIV - History of any opportunistic infection - to include but not limited to Pneumocystis carinii, aspergillosis, histoplasmosis, or atypical mycobacterium - History of porphyria - Diagnosis of SLE or seronegative spondyloarthropathy or any other form of concomitant arthritis (osteoarthritis is permitted) - Diagnosis of psoriasis unless rheumatoid factor positive - Any significant unstable medical condition considered a contraindication by investigator - Any participation in another investigational drug study during the 90 days preceding randomization. - Receipt of a live vaccine within 90 days of study entry. - History of oral or IV cyclophosphamide use - Life expectancy less than 2 years - Receipt of steroid injection, intravenous, intramuscular, or intraarticular, within 30 days of randomization. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Brampton (CRRC) | Brampton | Ontario |
Canada | University of Calgary (CRRC) | Calgary | Alberta |
Canada | Credit Valley Rheumatology | Missassauga | Ontario |
Canada | Hopital Notre Dame (CRRC) | Montreal | Quebec |
Canada | Newmarket (CRRC) | Newmarket | Ontario |
Canada | Crc-Chus (Crrc) | Sherbrooke | Quebec |
Canada | Mount Sinai Hospital (CRRC) | Toronto | Ontario |
Canada | Clinical Research and Arthritis Center | Windsor | Ontario |
Canada | University of Manitoba (CRRC) | Winnipeg | Manitoba |
United States | Bone, Spine Sports Clinic (RAIN) | Bismarck | North Dakota |
United States | Ralph H Johnson VA Medical Center, Charleston | Charleston | South Carolina |
United States | VA North Texas Health Care System, Dallas | Dallas | Texas |
United States | Geisinger Medical Center | Danville | Pennsylvania |
United States | St. Mary's/ Duluth Clinic Health System (RAIN) | Duluth | Minnesota |
United States | VA Medical Center, Fargo | Fargo | North Dakota |
United States | Lincoln Medical Center | Lincoln | Nebraska |
United States | VA Medical Center, Loma Linda | Loma Linda | California |
United States | VA Medical Center, Long Beach | Long Beach | California |
United States | Park Nicollet (RAIN) | Minneapolis | Minnesota |
United States | VA Medical Center, Minneapolis | Minneapolis | Minnesota |
United States | Univesity of Nebraska Medical Center | Omaha | Nebraska |
United States | VA Medical Center, Omaha | Omaha | Nebraska |
United States | VA Medical Center, Philadelphia | Philadelphia | Pennsylvania |
United States | VA Pittsburgh Health Care System | Pittsburgh | Pennsylvania |
United States | VA Medical Center, Portland | Portland | Oregon |
United States | Rapid City Medical Center (RAIN) | Rapid City | South Dakota |
United States | Mayo Clinic | Rochester | Minnesota |
United States | VA Salt Lake City Health Care System, Salt Lake City | Salt Lake City | Utah |
United States | VA Medical Center, San Francisco | San Francisco | California |
United States | Pacific Arthritis Center (RAIN) | Santa Maria | California |
United States | VA Greater Los Angeles HCS, Sepulveda | Sepulveda | California |
United States | Avera Research Institute (RAIN) | Sioux Falls | South Dakota |
United States | VA Medical Center, St Louis | St Louis | Missouri |
United States | Geisinger Medical Group - State College | State College | Pennsylvania |
United States | VA Medical Center, DC | Washington | District of Columbia |
United States | VA Medical & Regional Office Center, White River | White River Junction | Vermont |
United States | Geisinger Medical Group- Wilkes Barre | Wyoming Valley | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
VA Office of Research and Development | Canadian Institutes of Health Research (CIHR), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Rheumatoid Arthritis Investigational Network (RAIN) |
United States, Canada,
O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, Lew RA, Cannella AC, Kunkel G, Phibbs CS, Anis AH, Leatherman S, Keystone E; CSP 551 RACAT Investigators. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean 48-week Change in DAS28 | Average difference between 48-week and Baseline DAS28. The Disease Activity Score for 28 Joints (DAS28) is a well-validated composite outcome measure ranging from 2-10 (higher scores indicating more disease) that incorporates a tender and swollen joint count of 28 joints, a laboratory measure of systemic inflammation (ESR) and a patient-reported general assessment of health on a visual analog scale (ranging from 0-10cm) all into one measure. Low disease activity is defined as DAS28 = 3.2 units. |
48 weeks after baseline assessment | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |